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embolism (PE) in 2007-2011 were identified for whom out-patient pharmacy dis-
pensing data was available. Cancer, other risk factors and type and duration of 
anticoagulant treatment (LMWH and/or VKA) within 90 days of diagnosis and recur-
rence of VTE were assessed. Results: The study cohort included 1,581 VTE patients: 
1,053 with DVT and 528 with PE. For 70-86% of the VTE patients, dispensings of 
anticoagulant treatment were observed within 90 days. The median duration of anti-
coagulant dispensings among patients for whom both LMWH and VKA dispensings 
were observed was 3.5 months with provoked VTE and 3.7 months with unprovoked 
VTE. In these cohorts the observed median dispensing duration of (initial) LMWH 
treatment was 12 days. Recurrent VTE occurred mostly after discontinuation of anti-
coagulant treatment. Longer dispensing durations were observed among patients 
without recurrence. ConClusions: Treatment after VTE as captured in obser-
vational healthcare data generally follows the Dutch guidelines. However, many 
patients received LMWH dispensing covering periods longer than the recommended 
5-10 days. Furthermore, among patients with a VTE recurrence shorter duration of 
anticoagulant treatment was observed compared to patients without a recurrence.
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objeCtives: Oral anticoagulation (OAC) is the mainstay of stroke prevention in 
NVAF. With the arrival of NOACs as an alternative to VKA, there is interest in the 
utilization of these classes. This study aimed to describe treatment patterns and 
estimate persistence to VKA and NOACs in NVAF patients. Methods: Retrospective 
cohort study (Jan 2003-Dec 2013) of patients newly diagnosed with NVAF from the 
Badalona Serveis Assistencials database. Change in treatment line was defined 
as discontinuation (absence of prescription for ≥ 90 days) or switch. We calculated 
the cumulative incidence (95% CIs) of persistence after treatment initiation by 
treatment line, accounting for death as a competing risk. Results: Overall, 2,137 
patients initiated an OAC (VKA/NOAC) during the study period, with VKA most fre-
quently prescribed [2,127 patients (99.5%) vs. 300 patients (14.0%) initiating NOAC]. 
VKA was the predominant 1st line OAC following NVAF diagnosis (2,127; 99.5%). 
For patients initiating 2nd line treatments (589), half (298; 50.6%) restarted VKA 
after previous VKA treatment and cessation; and half (290; 49.2%) switched from 
VKA to a NOAC. Almost all NOAC initiations were patients previously treated with 
VKA (291/300 patients; 97%). Persistence to VKA was lower in 1st line than 2nd line 
patients (median time to discontinuation/switch: 156 vs. 181 days). Persistence to 
NOACs was not calculated for 1st line patients due to low numbers; but for patients 
initiating NOAC as 2ndline, the median time to NOAC discontinuation/switch was 
241 days. ConClusions: In this study, almost all patients initiating a 1st line OAC, 
initiated VKA, with essentially no first-line NOAC prescription. Unadjusted persis-
tence was best for patients initiating a NOAC as a 2nd line, and the shortest among 
patients initiating VKA as 1st line. As more patients are treated with NOACs in 
Spain, future research on treatment patterns should allow adjustment of persis-
tence comparisons between OACs.
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objeCtives: Poor adherence to cardiovascular therapy is increasingly demonstrated 
to contribute to poor health outcomes, leading to increased hospitalization rates. 
This study aims to quantify the potential economic implications of non-adherence 
to statins in Belgium, from the payer perspective. Methods: Adherence levels were 
estimated based on IMS Health Lifelink Treatment Dynamics database (IMS Health 
LTD). The number of prescription re-fills and total days covered by prescriptions 
were counted. Patients were assumed to take one pill per day. Dividing the total 
number of pills by the days of follow-up per patient resulted in the %-adherence 
level. The number of avoidable hospitalizations corresponding to each adherence 
level was determined by: the hospitalization risk difference between patients at 
80-100% adherence and less than 80% adherence (grouped per 20%, Sokol et al 
2005), and multiplying the number of patients in each of the five adherence lev-
els in Belgium (extrapolated from IMS Health LTD according to Pharmanet 2013 
report). The total avoidable cost attributable to non-adherence was estimated, by 
multiplying the number of avoided hospitalizations due to non-adherence with the 
average cost of a cardiovascular hospitalization in Belgium in 2014 (€ 5,865), adding 
the extra drug cost needed to obtain a 80-100% adherence. Results: Sixty-five 
percent of anonymized patients in the IMS Health LTD were below the acceptable 
80% adherence level. A total of 25,716 cardiovascular hospitalizations in Belgium 
were possibly attributable to lack of adherence to statins therapy. The estimated 
total avoidable costs related to hospitalization would be € 150.8Mn. If all patients 
raised their levels of adherence to 80-100%, treatment costs with statins would 
increase with € 68.5Mn. Thus, the estimated total amount of savings would be around 
€ 82.4Mn. ConClusions: Correcting poor adherence, not only in the cardiovascular 
area, can lead to important savings and give air to the healthcare payer to invest 
in innovative drugs.
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in the use of generic drugs.It is possible that even patients who have continually 
been prescribed generic drugs may switch to Protected Brand Drugs when they 
reimburse. The purpose of this study was to clarify this switch of patients to whom 
generic drugs had been prescribed to Brand Drugs using nationwide administrative 
data. Methods: Using dispensation data of pharmacies on an annual basis from 
April 2011 to December 2014, we identified all prescriptions for DM, Hypertension 
and Hyperlipidemia.1) We targeted patients prescribed only generic drugs between 
April and September each year, and who have dispensation records for three months 
or longer. 2) Where there was a change to the brand drug from a patient from Oct 
to March each year, this was defined as a drug switch. In terms of data analysis, we 
used SQL Server 2008 R2 for data handling and R for data analysis. Results: From 
among the patients with diabetes (N= 181,378), hypertension (343,188) and hyper-
lipidemia (343,188), those matching condition 1) in 2012 were patients with diabetes 
(n= 44,533), hypertension (132,165) and hyperlipidemia (81,455). 31% of all patients 
were continually prescribed only generic. The switch from generic to Protected 
Brand Drugs was higher in the younger 40-50 age group (p= 0.05) than in the elderly 
generation, and there was a higher rate of males (p= 0.05). ConClusions: The 
results of this study showed that when promoting drug substitution to generic drugs 
as a policy for reducing medical costs, it is also necessary to consider measures to 
counteract the shift to brand drugs.
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objeCtives: To study the pattern of prescription of antihypertensive agents among 
the patients visiting Cardiology department Methods: This is a cross sectional 
study conducted in collaboration with Department of Cardiology, College of Medical 
Sciences and Teaching Hospital, Bharatpur, Chitwan during the period of three 
months (1st January to 31st March 2015). All the patients attending the outpatient 
department of Cardiology and prescribed antihypertensive drugs were taken as 
sample. Results: Among the total 382 patients studied, the mean age was 58.53 ± 
12.295 years. Males contributed to 219 (57.32%) and females 163 (42.67%) cases. Mean 
body mass index was 23.64 ± 5.29 Kg/m2. Two hundred forty (63.35%) patients were 
given combination therapy and 140 (36.64%) were treated with a single drug. Two 
drug combination was given in 147 (38.48%) cases, three drugs in 63 (16.49%), four 
in 20(5.23) and five drugs in 12 (3.14%) cases. Angiotensin receptor antagonists (42 
or 30%), followed by calcium channel blockers (39 or 27.85%) were the most com-
monly prescribed drugs in 140 monotherapy cases. Combination of furosemide and 
spironolactone (101) was the most common single drug delivery system prescribed 
which was followed by metoprolol (88). ConClusions: The above findings would be 
useful for physicians and clinical pharmacologists in evaluating rational prescrib-
ing of the antihypertensive medicines. The inadequacy of control of blood pressure 
by monotherapy has increased the trend for combination therapy. The common 
antihypertensive used were angiotensin receptor antagonists.
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objeCtives: To assess adherence with therapeutic guidelines in the treatment of 
venous thromboembolism and pulmonary embolism in clinical practice. Methods: 
An observational retrospective analysis on six Local Health Units’ administrative 
and laboratory test databases was conducted, with around 2.7 Million beneficiar-
ies involved. Patients discharged alive from a hospitalization with a diagnosis of 
venous thromboembolism and pulmonary embolism between January 1st, 2010 and 
December 31st, 2012 were included. Since the index date (date of discharge), patients 
were characterised and followed-up basing on previous and following 12 months, 
respectively. Results: A total of 4,499 patients were included in the analysis. More 
prevalent therapeutic patterns and sequences occurred as follows. Among included 
patients, considering all the follow-up period, 33% had heparin only (average dura-
tion of heparin treatment equal to 143 days), 26% had vitamin K antagonist (VKA) 
only, 4% had fondaparinux only, and 12% had none of the previous treatments. 
Eight percent of included patients were initially prescribed for VKA and combined 
heparin during the follow-up period (average duration of heparin treatment equal 
to 76 days), 4% were initially prescribed for heparin (average duration of hepa-
rin treatment equal to 150 days) and combined VKA during the follow-up period. 
Four percent of included patients were initially prescribed for VKA and switched 
to heparin during the follow-up period (average duration of heparin treatment 
equal to 99 days) while 3% were initially prescribed for heparin (average duration 
of heparin treatment equal to 75 days) and switched to VKA during the follow-up 
period. ConClusions: Adherence with therapeutic guidelines in the treatment of 
venous thromboembolism and pulmonary embolism in clinical practice appeared 
unsatisfactory since a high percentage of patients are treated with heparins for time 
period longer than recommended instead of switching to VKAs.
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objeCtives: To describe initial anticoagulant treatment after venous thrombo-
embolism (VTE) as recorded in electronic healthcare records and relate this to 
the underlying risk factors, guidelines and recurrence rates. Methods: From the 
PHARMO GP Database, patients with deep venous thrombosis (DVT) or pulmonary 
